Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (794)	1/1/2000 4:47:00 PM
From: aknahow	Respond to of 3158

See that MTC & PNU have agreed on a mutual break up fee of $575 million. Using a fraction of $100 million makes me think the spend a lot more time arriving at a scientific number. <g> Understand the need for a penalty but can't one believe that one or two quarters of net earnings would be more than adequate to penalize the party that walked without good reason? Now that MTC is spoken for who will DD go after?

To: Biomaven who wrote (794)	1/14/2000 9:11:00 AM
From: aknahow	Read Replies (1) \| Respond to of 3158

While we have all see this, I am sttill posting it. Glaxo/Smith Kline dailynews.yahoo.com Last year many thought a lot of mergers would occur among the medium sized biotechs. I did not think so, as I saw it as big fish eating the smaller when they were not preoccupied with going after one another. However, I made no money by getting this right, and never called a potential merger, correctly, in advance of the actual news. See more of the same this year except that if the biotech boom inflates prices, those companies that I thought could not spend the resources in trying to merge with one another will find it possible to hire outside help. The higher stock values should incent some to go looking for acquisitions.